Indivior

ISIN GB00BN4HT335

 | 

WKN A3DWFC

Market cap (in EUR)
3,854 m
Country
United States
Sector
Healthcare
Dividend yield
0.00%
 

Overview

Description

Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in North Chesterfield, VA.
Show more Show less
Healthcare Biopharmaceuticals Other Biopharmaceuticals United States

Financials

Key metrics

Market capitalisation, EUR 3,854 m
EPS, EUR 0.91
P/B ratio 142.2
P/E ratio 36.2
Dividend yield 0.00%

Income statement (2024)

Revenue, EUR 1,098 m
Net income, EUR 2 m
Profit margin 0.17%

What ETF is Indivior in?

There are 3 ETFs which contain Indivior. All of these ETFs are listed in the table below. The ETF with the largest weighting of Indivior is the iShares Nasdaq US Biotechnology UCITS ETF USD (Dist).
ETF Weight Investment focus Fund size (in m EUR)
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) 0.31%
Equity
United States
Health Care
Biotech
44
Vanguard ESG Global All Cap UCITS ETF (USD) Distributing 0.01%
Equity
World
Social/Environmental
485
Vanguard ESG North America All Cap UCITS ETF (USD) Distributing 0.01%
Equity
North America
Social/Environmental
27
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.

Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.